Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (October 2005)
19 slides from Biotron's shareholder meeting presentation, Oct 14, 2005
Slide 1: Presentation to Annual General Meeting (ASX cover letter)
BIOTCL OM timitea A.B.N, 60 086 399 144 Level 8, 261 George Street Sydney NSW 2000 Tel: (61-2) 9247 8212 Fax: (61-2) 9247 3932 E-mail: pnightingale@biotron.com.au Website: www.biotren.com.au 14 October 2005 The Manager Companies Australian Stock Exchange Limited 20 Bridge Street SYDNEY NSW 2000 (19
Slide 2: Biotron AGM 14 Oct 2005
BiotTtronmn AGM 14 Oct 2005
Slide 3: Developing a pipeline targeting diseases with unmet medical needs
“ RICTRON + + Developing a pipeline - Pe apa . _ targeting diseases with unmet medical needs : / and. large, expanding world markets. / . Current major focus. is viral diseases, in ee HIV-1 and Hepatitis C virus. _. Biotron Limited
Slide 4: People living with HIV/AIDS
ar 8 million people with HIV/AIDS at end of 2003 _ 4 8 million Pe were newly i infected with HIV: in 203 ~—i«s ~~ / . : In 2003 2.9 maillion people died of - _ _HIV/AIDS-related causes. _ . o US market alone worth >USS3, a billion p. a. B ep Vamited
Slide 5: FDA Approved HIV Therapeutics
FDA APPROVED HIV THERAPEUTICS | Entry Inhibitor 17 RT Inhibitors —_ 10 Protease Inhibitors Protein processing —\g& Double-stranded and virus assembly proviral DNA / proteins ® ANA / * 2 6 Reverse transcriptase Coat-protein glycosyl De
Slide 6: Need for New HIV Therapies
NEED FOR NEW HIV THERAPIES Majority of oe develop resistance to existing | : HIV drugs. Up to 26% newly diagnosed patients have - _ resistant strains of virus; up to 78% of late-stage __ patients develop resistance to existing therapies. The development of resistant viral strains is one of the main
Slide 7: BIT Drugs Target Different Stage of HIV Life Cycle
BIT DRUGS TARGET DIFFERENT STAGE OF HIV LIFE CYCLE iw B:%. 6 1, & is Binding to CD4 teceptor Mature HIV Budding virus mt Cytopiasm U Entry and partial uricdating Shot g os ° | Reverse transcription 9o0090 ooo0000 Transiocation to nucleus ite BIT compounds work at a late stage of the virus life cycle
Slide 8: BIT - First in Class Vpu Inhibitors
BIT - “FIRST IN¢ CLASS” VPU | INHIBITORS. Biotron Limited
Slide 9: BIT Compounds Active in Viral Reservoir Cells
BIT COMPOUNDS ACTIVE IN- VIRAL RESERVOIR CELLS | -Not targeted ae current HIV therapies -Contribute to long-term disease Sepia in a> dementia Biotron Limited
Slide 10: Development of New Class of Anti-HIV Drugs
_ DEVELOPMENT OF NEW CLASS OF a TI-HIV DRUGS - » Started with BITO09 + Designed, synthesized and screened library of >200 compounds ~40 compounds had improved ae compared to BITO09 Lead optimisation and selection program . successfully completed _ —* Selected a lead compound BIT225 to progress into
Slide 11: BIT225
. ee o BIT225— High oral bioavailability (~68%) - Good stability and half-life in vivo Excellent safety profile in animals Good activity against HIV in vitro | “Active against resistant strains of HIV Simple chemistry. for manufacture ‘Novel compound; new w mechanism of action. -Biotron L imited
Slide 12: BIT225 development steps toward Phase 1/1a trial
_ Finalised. contra for panuiecuue of drug ige) GMP standards; manufacture underway — . Complete a6 -day. safety studies j in animals oF inalise Phase 1/la trial site and design — Complete’ trial (short-term study) Biotron Limited
Slide 13: Hepatitis C Virus (HCV)
HEPATITIS C VIRUS (HCV) 4m in US (2.7m chronic infection); 170m worldwide 4x more prevalent than HIV Worldwide market ~US$2.8 billion US surgeon general considers hepatitis C is one of the most significant public health threats facing US. The chronic infection predisposes to the development of cirrh
Slide 14: BIT - Targeting HCV p7
BIT —- TARGETING HCV P7_ NNN LL NNN LLL co : oo Daten | jit |
Slide 15: Biotron's HCV Program
BIOTRON’S HCV PROGRAM Developed rapid bacterial cell- based assay to screen against p7 target Developed surrogate mammalian-cell based infectivity assay for HCV > Collaboration with Prof Eric Gowans at Burnet — Institute, Melbourne : Identified several lead candidates targeting HCV-p1 Commenced a le
Slide 16: Biotron's Antiviral Strategy
"BIOTRON’S ANTIVIRAL _ STRATEGY | . » Progress HIV-Vpu inhibitor to the cine: as - fast as possible for proof-of-concept human — trial - + Progress HCV-p7 inhibitor either i in parallel or soon aiter (resources permitting) | Partner ata stage to maximise value for 0 shareholders _ : _ Biotron Limite
Slide 17: C-Test Cancer Diagnostic
C- TEST CAN CER DIAGNOSTIC Cancer is a major killer * Global market for cancer diagnostics i is US$3 billion Direct costs for cancer is US$37 billion i in USA alone Incidence increasing due to aging population — Potential to reduce these costs by early diagnosis ¢ Most cancer diagnostics are slow, i
Slide 18: C-Test Update
_C-TEST UPDATE r | ident fed class of molecules found | in bload that are modified on cancer cells . Initial focus on prostate cancer — identified : several biomarkers specific to this disease * Identification of biomarkers for. colorectal — cancer in progress — : Focused on developing ape processes
Slide 19: Cash position and additional revenues
| | ° $2. lm cash, as ray 2005 _. Additional revenues from Start and BIF grants © . . Awarded $200, 000 rant fom ACT government for C-Test development _ -- ocused on commercialising projects to build strong, sustainable base under BIT, _ / maximising returns to shareholders |